In a melanoma mouse model, an engineered oncolytic virus that co‐expresses a PD‐L1 inhibitor and GM‐CSF activates tumor neoantigen‐specific T cell responses, increasing the PD‐1/PD‐L1 blockade therapy.17 This evidence concerns the gene CD274 and melanoma.